The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstrated the efficacy and safety of fingolimod in patients with multiple sclerosis (MS). We present an observational study that validates these trials findings in a real-world setting, whereby the effecti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5409154?pdf=render |
| _version_ | 1818298035002671104 |
|---|---|
| author | Guillermo Izquierdo Fátima Damas Maria Dolores Páramo Juan Luis Ruiz-Peña Guillermo Navarro |
| author_facet | Guillermo Izquierdo Fátima Damas Maria Dolores Páramo Juan Luis Ruiz-Peña Guillermo Navarro |
| author_sort | Guillermo Izquierdo |
| collection | DOAJ |
| description | Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstrated the efficacy and safety of fingolimod in patients with multiple sclerosis (MS). We present an observational study that validates these trials findings in a real-world setting, whereby the effectiveness and safety of fingolimod was assessed in Seville's' (Spain) clinical practice. This retrospective study in MS patients assessed effectiveness (relapses, EDSS, gadolinium-enhancing T1 and new/enlarged T2-weighted lesions): total cohort (n = 249) and stratified according to prior treatment (glatiramer acetate/interferon beta-1 [immunomodulator], natalizumab, naïve), gender, basal EDSS score, basal Gd+ lesions, ARR prior to treatment, age at treatment initiation and number of prior treatments. A multivariante model was used to assess the ARR with baseline characteristics. The safety profile (adverse events [AEs]) was also described. Fingolimod reduced the annualized relapse rate (ARR) by 75%, 67% and 85% in the total cohort, patients previously treated with immunomodulatory and naïve patients (p<0.0001 all cases). However, patients previously treated with natalizumab kept a constant ARR. The ARR results and the consequent increase in the proportion of relapse-free patients were independent of the age at treatment initiation, number of prior treatments, gender and basal Gd+ lesions. Although fingolimod was effective regardless the basal EDSS score and ARR prior to fingolimod treatment, better outcomes were observed in patients with basal EDSS score <3 (0.2 vs. 0.4; p = 0.0244) and ARR ≥ 2 prior to fingolimod treatment (p = 0.0338). Only the basal EDSS score was association with ARR in the first 24 months of fingolimod treatment in the multivariante model (p = 0.0439). The cumulative probability of disability progression was 20% (month-24) in the total cohort, and was independent from prior treatment, age at treatment initiation, number of prior treatments, gender, basal EDSS score, basal Gd+ lesions and ARR prior to treatment. The real-world fingolimod benefits observed in this study seem to be similar than those observed in previous clinical trials. |
| first_indexed | 2024-12-13T04:28:55Z |
| format | Article |
| id | doaj.art-7efc60d99b3e425fa71d69d6aa53b380 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T04:28:55Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7efc60d99b3e425fa71d69d6aa53b3802022-12-21T23:59:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01124e017617410.1371/journal.pone.0176174The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.Guillermo IzquierdoFátima DamasMaria Dolores PáramoJuan Luis Ruiz-PeñaGuillermo NavarroFingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstrated the efficacy and safety of fingolimod in patients with multiple sclerosis (MS). We present an observational study that validates these trials findings in a real-world setting, whereby the effectiveness and safety of fingolimod was assessed in Seville's' (Spain) clinical practice. This retrospective study in MS patients assessed effectiveness (relapses, EDSS, gadolinium-enhancing T1 and new/enlarged T2-weighted lesions): total cohort (n = 249) and stratified according to prior treatment (glatiramer acetate/interferon beta-1 [immunomodulator], natalizumab, naïve), gender, basal EDSS score, basal Gd+ lesions, ARR prior to treatment, age at treatment initiation and number of prior treatments. A multivariante model was used to assess the ARR with baseline characteristics. The safety profile (adverse events [AEs]) was also described. Fingolimod reduced the annualized relapse rate (ARR) by 75%, 67% and 85% in the total cohort, patients previously treated with immunomodulatory and naïve patients (p<0.0001 all cases). However, patients previously treated with natalizumab kept a constant ARR. The ARR results and the consequent increase in the proportion of relapse-free patients were independent of the age at treatment initiation, number of prior treatments, gender and basal Gd+ lesions. Although fingolimod was effective regardless the basal EDSS score and ARR prior to fingolimod treatment, better outcomes were observed in patients with basal EDSS score <3 (0.2 vs. 0.4; p = 0.0244) and ARR ≥ 2 prior to fingolimod treatment (p = 0.0338). Only the basal EDSS score was association with ARR in the first 24 months of fingolimod treatment in the multivariante model (p = 0.0439). The cumulative probability of disability progression was 20% (month-24) in the total cohort, and was independent from prior treatment, age at treatment initiation, number of prior treatments, gender, basal EDSS score, basal Gd+ lesions and ARR prior to treatment. The real-world fingolimod benefits observed in this study seem to be similar than those observed in previous clinical trials.http://europepmc.org/articles/PMC5409154?pdf=render |
| spellingShingle | Guillermo Izquierdo Fátima Damas Maria Dolores Páramo Juan Luis Ruiz-Peña Guillermo Navarro The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. PLoS ONE |
| title | The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. |
| title_full | The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. |
| title_fullStr | The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. |
| title_full_unstemmed | The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. |
| title_short | The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. |
| title_sort | real world effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis patients an observational study |
| url | http://europepmc.org/articles/PMC5409154?pdf=render |
| work_keys_str_mv | AT guillermoizquierdo therealworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT fatimadamas therealworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT mariadoloresparamo therealworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT juanluisruizpena therealworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT guillermonavarro therealworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT guillermoizquierdo realworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT fatimadamas realworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT mariadoloresparamo realworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT juanluisruizpena realworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy AT guillermonavarro realworldeffectivenessandsafetyoffingolimodinrelapsingremittingmultiplesclerosispatientsanobservationalstudy |